# Guido Neels

> Guido Neels is a Series C investor at Essex Woodlands Healthcare Partners backing Health Care. See 8 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [Essex Woodlands Healthcare Partners](https://shizune.co/investors/profile/essex-woodlands-health-ventures)
- Total investments: 8
- Last investment: Aug 2011
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/guido-neels-7aa09a9

Guido Neels is a Series C investor at Essex Woodlands Healthcare Partners focused on Health Care and Biotechnology. Guido Neels has over 40 years of experience developing international healthcare businesses. From May 2004 until retiring in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation, a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant’s fouroperating units - Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to May 2004, he was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 to December 2002, he was President of Guidant for Europe, Middle East, Africa and Canada.He previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 to 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co., Mr. Neels held general management, sales and marketing positions at Lilly in the U.S. and Europe. From 1972 to 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the U.S.Mr. Neels currently serves as the Interim CEO of Bioventus, the Chairman of the Board of Directors for Oraya Therapeutics, and serves on the Board of Directors for Entellus Medical, ClearVascular, and Endologix. In addition to the portfolio company boards on which he serves, Mr. Neels also serves on the Board of Directors for Arsenal Medical, EndGenitor Technologies, and Christel House International.Mr. Neels holds a Business Engineering degree from the University of Leuven in Belgium and a Master of Business Administration degree from Stanford University. Mr. Neels joined Essex Woodlands as a Partner in August 2006, was promoted to Managing Director in 2008, and was appointed to Operating Partner in February 2013.

## Contacts

5 contacts available for Guido Neels: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/guido-j-neels?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 38% |
| Biotechnology | 3 | 38% |
| Medical Device | 2 | 25% |
| Medical | 1 | 13% |
| Therapeutics | 1 | 13% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 25% |
| Series A | 1 | 13% |
| Series B | 1 | 13% |
| Series D | 1 | 13% |
| Series E | 1 | 13% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Entellus Medical | Entellus Medical is focused on providing unique solutions to the unmet needs of the ENT (ear, nose and throat) physician, their patients, and payers through the development of innovative device technology and treatment solutions. Entellus is based in Maple Grove, MN and markets products throughout the United States.Entellus Medical works closelywith leading researchers and clinicians to develop solutions that benefit patients, physicians, and payers. Entellus provides a simple, direct and effective treatment for Chronic Rhinosinusitis (CRS) that is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia.Entellus recently introduced FinESSâ„¢ Sinus Treatment, a simple and direct approach to effectively treat patients with CRS. FinESS can be performed under local anesthesia, with or without light sedation, and remodels the maxillary ostium and the ethmoid infundibulum using a micro endoscope and a small balloon catheter. Unlike sinus surgery techniques, FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment time with very little pain or bleeding. Recovery time is usually one to two days with many patients resuming normal activity within a day. | $35M | Series E | Aug 17, 2011 |  |
| Endologix | Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-likeenlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. | $15M | Post-IPO Equity | Oct 27, 2010 |  |
| Entellus Medical | Entellus Medical is focused on providing unique solutions to the unmet needs of the ENT (ear, nose and throat) physician, their patients, and payers through the development of innovative device technology and treatment solutions. Entellus is based in Maple Grove, MN and markets products throughout the United States.Entellus Medical works closelywith leading researchers and clinicians to develop solutions that benefit patients, physicians, and payers. Entellus provides a simple, direct and effective treatment for Chronic Rhinosinusitis (CRS) that is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia.Entellus recently introduced FinESSâ„¢ Sinus Treatment, a simple and direct approach to effectively treat patients with CRS. FinESS can be performed under local anesthesia, with or without light sedation, and remodels the maxillary ostium and the ethmoid infundibulum using a micro endoscope and a small balloon catheter. Unlike sinus surgery techniques, FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment time with very little pain or bleeding. Recovery time is usually one to two days with many patients resuming normal activity within a day. | $30M | Series D | Nov 17, 2009 |  |
| Oraya Therapeutics | Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye. | $42M | Series C | Jul 20, 2009 |  |
| ROX Medical | ROX Medical is an early phase medical device company that is pioneering an innovative treatment for Chronic Obstructive Pulmonary Disease (COPD). Their therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula. | $33M | Series C | Jun 13, 2008 |  |
| Nellix |  | $6.5M | Series C | Mar 15, 2008 |  |
| Oraya Therapeutics | Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye. | $18M | Series B | Jan 11, 2008 |  |
| Oraya Therapeutics | Oraya Therapeutics is currently testing its first application of the IRay system. Oraya Therapeutics develops noninvasive robotically controlled treatments for inflammatory and neovascular diseases of the eye. | $4M | Series A | Jun 18, 2007 |  |

8 of 8 investments shown.

## Co-investors
- [Split Rock Partners](https://shizune.co/investors/profile/split-rock-partners) — VC Fund, 2 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 2 deals together
- Synergy Life Science Partner — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 1 deal together
- [Prism Venture Management](https://shizune.co/investors/profile/prism-venture-management) — VC Fund, 1 deal together
- [Scale Venture Partners](https://shizune.co/investors/profile/scale-venture-partners) — VC Fund, 1 deal together

## About Essex Woodlands Healthcare Partners

VC Fund · Palo Alto, United States

Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world's largest and most established healthcare venture capital firms. The team is comprised of 23 professionals withprincipal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience.For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.

5 contacts available at Essex Woodlands Healthcare Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Brooks Andrews | Associate | — |
| Guido Neels | Managing Director | — |
| Immanuel Thangaraj | Managing Director | — |
| Martin Sutter | Managing Director, Co-Founder | — |
| Robert White | Operating Partner | — |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Guido Neels invest in?

Guido Neels invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Guido Neels?

Public channels for Guido Neels include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Guido Neels last invest?

The most recent investment recorded for Guido Neels closed in Aug 2011. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co